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Objectives This study evaluated the ability of the bedside test Hemochron Jr. Hemonox (International Technidyne Corporation,
Edison, New Jersey) to identify patients with insufficient anti-Xa activity level in the catheterization laboratory.
Background Inadequate anticoagulation in patients undergoing percutaneous coronary intervention (PCI) is associated with
increased periprocedural ischemic events.
Methods In 296 unselected patients undergoing catheterization and/or PCI, whole blood Hemonox clotting time (CT) and
activated partial thromboplastin time (aPTT) were measured at baseline (T1) and 10 min after the intravenous
administration of enoxaparin (T2) in patients receiving additional enoxaparin and compared with plasma chro-
mogenic anti-Xa activity level.
Results Median values were 0.1 IU/ml (interquartile range [IQR]: 0.1 to 0.1 IU/ml) and 0.87 IU/ml (IQR: 0.74 to 1.03 IU/ml)
for anti-Xa; 74 s (IQR: 70 to 81 s) and 143 s (IQR: 114 to 206 s) for Hemonox CT; and 44 s (IQR: 39 to 50 s) and 72 s
(IQR: 58 to 93 s) for aPTT at T1 and T2, respectively. When using Hemonox CT to discriminate patients with anti-Xa
level 0.5 IU/ml, the area under the receiver operating characteristic curve was 0.95  0.01 (95% confidence inter-
val [CI]: 0.93 to 0.97) versus 0.89  0.01 (95% CI: 0.86 to 0.92) for aPTT. The threshold value of 120 s was associ-
ated with a 94.9% (95% CI: 91.1% to 97.4%) sensitivity and a 73.3% (95% CI: 67.6% to 78.5%) specificity to detect
patients with inadequate anti-Xa level (0.5 IU/ml) and positive predictive and negative predictive values of 73.9%
(95% CI: 68.7% to 79.0%) and 94.78% (95% CI: 91.8% to 97.8%), respectively.
Conclusions Hemonox CT appears to be a fast and reliable bedside test for detecting patients insufficiently anticoagulated
and needing adjustment of anticoagulation therapy with enoxaparin before PCI. (J Am Coll Cardiol 2010;55:
617–25) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.077i
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an many countries, low molecular weight heparin (LMWH)
noxaparin is the most common form of heparin used in the
reatment of acute coronary syndromes (ACS) (1). Current
uidelines from the European Society of Cardiology and other
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Manuscript received June 23, 2009; revised manuscript received August 27, 2009,
ccepted August 30, 2009.nternational societies strongly recommend enoxaparin in the
reatment of ST-segment elevation myocardial infarction
STEMI) in association with fibrinolysis (Class I, Level of
vidence: A), in the treatment of non–ST-segment elevation
CS for invasive strategy (Class IIa, Level of Evidence: B),
nd for conservative strategy (Class I, Level of Evidence: B)
2). Additionally, enoxaparin is being evaluated for primary
ercutaneous coronary intervention (PCI) in STEMI patients
NCT00718471). Recently, the safety and efficacy of intrave-
ous LMWH anticoagulation therapy for patients undergoing
ither urgent or elective PCI has been demonstrated in a
umber of trials (3). Compared with unfractionated heparin
UFH), enoxaparin provides more predictive and more stable
nticoagulation therapy. In the STEEPLE (Safety and Effi-
acy of Enoxaparin in Percutaneous Coronary Intervention
atients, an International Randomized Evaluation) trial, target
nticoagulation levels were achieved in 86% of patients receiv-
ng enoxaparin without monitoring, compared with 20% of
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Bedside Enoxaparin Monitoring February 16, 2010:617–25patients receiving UFH with ac-
tivated clotting time monitoring,
leading to reduced rates of bleed-
ing with enoxaparin (4).
However, many physicians have
considered the absence of vali-
dated anticoagulation monitoring
before catheterization as a limita-
tion to the use of enoxaparin for
PCI. Chromogenic anti-Xa activ-
ity level is the standard laboratory
assay for monitoring the anticoag-
ulant effect of LMWH but is not
available at the bedside, and acti-
vated clotting time is not discrimi-
nant enough for enoxaparin anti-
coagulation therapy (5). Recently a
new, easy to use microcoagulation
point-of-care assay, Hemochron
Jr. Hemonox (International Tech-
nidyne Corporation, Edison, New
Jersey), was developed and dem-
onstrated promising results in a
small-sized study performed in
elective PCI (6).
We decided to evaluate the
ability of the Hemonox test to
dentify patients with an anti-Xa activity level out of the
herapeutic range during catheterization and/or PCI, a
Figure 1 Flow Chart Representing Operation Clinical Events
The majority of patients (71.3%) received intravenous (IV) enoxaparin at the dose
mg/kg/12 h (0.65 mg/kg/12 h in the case of renal impairment), and 7.1% receiv
between 8 and 12 h). vit-K  vitamin K.
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
aPTT  activated partial
thromboplastin time
CI  confidence interval
CT  clotting time
IQR  interquartile range
IV  intravenous
LMWH  low molecular
weight heparin
MACCE  major
cardiovascular and
cerebrovascular events
PCI  percutaneous
coronary intervention
ROC  receiver-operating
characteristic
SQ  subcutaneous
STEMI  ST-segment
elevation myocardial
infarction
UFH  unfractionated
heparinituation associated with a poor prognosis when measured
ith the reference chromogenic technique (7,8).
ethods
atient population. Patients were eligible if all of the
ollowing criteria were met: 1)18 years of age; 2) provided
igned informed consent; 3) scheduled to undergo elective
r urgent cardiac catheterization with possible ad hoc PCI;
nd 4) had received therapeutic subcutaneous (SQ) doses of
noxaparin or intravenous (IV) bolus of enoxaparin in the
atheterization laboratory. Patients were excluded if they
ad received UFH, warfarin, or any other anticoagulant
efore catheterization or if they had known bleeding within
he past month. The study initially enrolled 313 consecutive
atients, of whom 17 were excluded because they did not
eceive any enoxaparin before or during catheterization (n
1) or were still receiving vitamin-K antagonist (n  6)
Fig. 1). Fourteen patients had an unknown anticoagulation
tatus (transfer patients, urgent cases from the emergency
epartment) but were kept in the study as a separate group.
This study was approved by the institutional review board
f the Pitié-Salpêtrière Hospital in Paris (CPP), France.
tudy design and medication. Study anticoagulation pro-
ocol is presented in Figure 2. Patients received upstream
Q enoxaparin treatment before admission to the catheter-
zation laboratory at 1 mg/kg/12 h (patients with normal
enal function) or at 0.65 mg/kg/12 h (patients with renal
ailure defined as creatinine clearance 30 ml/min) (9),
mg/kg, 21.6% received subcutaneous (SQ) enoxaparin only at the dose of 1
additional 0.25 mg/kg IV dose in addition to SQ enoxaparin (last injectionof 0.5
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February 16, 2010:617–25 Bedside Enoxaparin Monitoringorresponding to a previously validated (10) dose adjust-
ent for renal failure although slightly different than the
ood and Drug Administration recommendation. Patients
rom this group received no further anticoagulation therapy
f the last SQ dose was given within 8 h of the catheteriza-
ion. An additional 0.25 mg/kg IV bolus was given to
atients who had their last SQ enoxaparin dose 8 to 12 h
efore catheterization. Patients presenting at the catheter-
zation laboratory for elective or urgent/primary PCI who
ad no prior anticoagulation therapy with enoxaparin or
atients with unknown anticoagulation status received a
ingle IV bolus of enoxaparin (0.5 mg/kg) before the
rocedure. Flush for catheters contained enoxaparin (5
U/ml) and dipyridamole (40 mg/l). Aspirin, clopidogrel,
nd glycoprotein IIb/IIIa inhibitor use was left to the
iscretion of the physician in charge of the patient. Cath-
terization was performed and followed by ad hoc PCI
hen needed.
lood samples. Patients without prior anticoagulation
herapy and patients presenting 8 to 12 h after the last SQ
njection had blood samples drawn from the arterial sheath
t 2 different time points for point-of-care (Hemonox and
ctivated partial thromboplastin time [aPTT] tested on
resh whole blood) and chromogenic anti-Xa (tested on
lasma) evaluations. The first blood sample (T1) was drawn
Figure 2 Study Design
The first blood sample (T1) was drawn immediately after sheath insertion, and the
needed, according to the anticoagulation protocol. Patients previously treated with
before percutaneous coronary intervention (PCI), as no additional anticoagulation t
activated partial thromboplastin time; Axa  anti-Xa activity; Cl Creat  renal cleaust after sheath insertion and before the IV bolus, and the tecond draw (T2) was obtained 10 min after the IV
noxaparin bolus. Patients previously treated with SQ enox-
parin and presenting within 8 h from the last injection had
draw just before PCI (T2), as no additional anticoagula-
ion was administered to these patients.
easurements. The Hemonox clotting time (CT) and
PTT were measured immediately after sampling, using
.25 ml of blood for each measurement. The remaining 4.5
l of the blood was collected in Vacutainer tubes (Becton
ickinson, Franklin Lakes, New Jersey) containing triso-
ium citrate 0.129 mol/l for chromogenic measurement of
nti-Xa level. Both Hemonox CT and aPTT were measured
t bedside using the Hemochron Jr. Signature  Whole
lood Microcoagulation System with ITC software version
.2 (International Technidyne Corporation). The Hemonox
ses a proprietary lipidated recombinant rabbit brain tissue
actor-based reagent (Pel-Freez Corp., Rogers, Arkansas)
nd formulation buffer, which has been optimized for
valuation of the anticoagulation effect of enoxaparin. A
eries of light-emitting diode optical detectors aligned with
he test channel of the disposable Hemonox cuvette detect
he movement of blood in the channel, and its cessation
hen clotting occurs, and then the instrument reports the
hole blood CT value in seconds. The results obtained from
his study were for research purposes only and were not
d draw (T2) was obtained 10 min after the IV enoxaparin (Enox) bolus, if
oxaparin and presenting within 8 h from the last injection had 1 draw (T2) just
was administered to these patients. ACS  acute coronary syndrome; aPTT 
of creatinine; CT  clotting time; other abbreviations as in Figure 1.secon
SQ en
herapy
ranceaken into consideration in patient management.
f
c
1
X
D
b
p
n
u
t
w
h
I
C
t
v
d
r
b
w
S
p
m
t
P
t
W
c
C
p
f
b
S
C
R
T
p
r
p
B
D
r
b
n
S
PB
V
620 Silvain et al. JACC Vol. 55, No. 7, 2010
Bedside Enoxaparin Monitoring February 16, 2010:617–25Chromogenic anti-Xa activity measurements were per-
ormed on platelet-poor plasma, which was prepared by
entrifugation of blood samples at 3,500 g for 20 min at
0°C, using the amidolytic assay (CBS 52.44, bovine factor
a reagents, and STA [simultaneous thermal analyzers],
iagnostica Stago, Parsippany, New Jersey).
The therapeutic range of anti-Xa levels was considered to
e between 0.5 and 1.8 IU/ml. The lower limit was based on
rior studies of target anti-Xa levels in patients with
aseline CharacteristicsTable 1 Baseline Characteristics
Study Population
(n  296)
Demographics
Age, yrs 61.5 13.7
Elderly, age 75 yrs 46 (15.5)
Sex, male 224 (75.7)
Risk factors
Active smoker 54 (18.2)
Diabetes mellitus 69 (23.3)
Hypertension 167 (56.4)
Dyslipidemia 174 (58.8)
BMI 26.7 4.9
Obesity, BMI 30 kg/m2 49 (16.5)
Overweight, BMI 25 kg/m2 118 (39.9)
Creatinine, M/ml 103.8 71
Creatinine Cl, ml/min 84 39
Renal insufficiency, Cl 60 ml/min 74 (25)
Renal insufficiency, Cl 30 ml/min 12 (4)
Medical history
ACS 62 (20.9)
Angioplasty 88 (29.7)
Stenting 78 (26.3)
DES 37 (12.5)
CABG 15 (5.1)
Stroke 18 (6.1)
PAD 31 (10.5)
Clinical presentation
Stable angina or asymptomatic
patients
69 (23.3)
Unstable angina 54 (18.2)
NSTEMI, positive troponin 49 (17.4)
STEMI 17 (5.7)
Other 107 (36.1)
Antithrombotic treatment
ASA 248 (83.8)
Clopidogrel 197 (66.5)
GP IIb/IIIa inhibitor 12 (4.0)
Other medications
Beta-blocker 188 (63.5)
ACE inhibitor 130 (43.9)
ARAII 60 (20.3)
Lipid-lowering agent 233 (78.7)
ata presented as mean  SD or n (%).
ACE  angiotensin converting enzyme; ACS  acute coronary syndrome; ARAII  angiotensin II
eceptor antagonist; ASA  acetylsalicylic acid; BMI  body mass index; CABG  coronary artery
ypass graft surgery; Cl  clearance; DES  drug-eluting stent; GP  glycoprotein; NSTEMI 
on–ST-segment elevation myocardial infarction; PAD  peripheral arterial disease; STEMI 
T-segment elevation myocardial infarction.on–ST-segment elevation ACS (7,11), and in patients ndergoing PCI (12–14). The upper value corresponds to
he 75th percentile of peak anti-Xa values in patients treated
ith 1.25 mg/kg every 12 h who did not experience major
emorrhage in the TIMI (Thrombolysis In Myocardial
nfarction) 11A study (8).
linical follow-up. Thirty-day follow-up was realized
hrough consult and/or telephone interviews. Major cardio-
ascular and cerebrovascular events (MACCE), including
eath, stroke, recurrent myocardial infarction, urgent
evascularization, and definite and probable stent throm-
osis (Academic Research Consortium definition), as
ell as major and minor bleeding were reported.
tatistical analysis. Categorical variables were expressed as
ercentages, and continuous variables as mean  SD and as
edian with interquartile range (IQR) (25th to 75th percen-
iles) for biological values (Hemonox CT, aPTT, and anti-Xa).
otential associations between clinical and biological parame-
ers were tested by unvaried procedures using the Mann-
hitney U test. Receiver-operating characteristic (ROC)
urves were drawn to determine cutoff values of the Hemonox
T as a diagnostic test for monitoring anticoagulation com-
ared with anti-Xa activity levels. We used the Spearman test
or nonparametric values to calculate correlation between
iological measurements. All analyses were performed with
tatView 5.0 SAS software (SAS Institute, Cary, North
arolina).
esults
he baseline characteristics are shown in Table 1. Details of
rocedure, angiographic results, and biological results are
eported in Table 2. Follow-up was achieved in 97% of
atients at 30 days.
rocedure Characteristics andi logical Me surement at T1 and T2Table 2 Procedur Characteristics andBiological Measurement at T1 and T2
Study Population
(n  296)
Angiography
Nonsignificant lesion or normal angiogram 142 (47.9)
Patients with at least 1 significant lesion 157 (52.1)
Revascularization
CABG (arterial or saphenous graft) 4 (1.3)
PCI/stenting 165 (55.7)
Anticoagulation and biology, min
Time sheath insertion to T1 6.3 (3.8)
Time T1 to T2 11.5 (7.1)
Biological measurement
Hemonox CT T1, s (n  229) 74 [70–81] (58–444)
Hemonox CT T2, s (n  289) 143 [114–206] (57–749)
Anti-Xa activity T1, IU/ml (n  219) 0.1 [0.1–0.1] (0.1–0.96)
Anti-Xa activity T2, IU/ml (n  269) 0.87 [0.74–1.03] (0.1–1.9)
aPTT T1, s (n  225) 44 [39–50] (20–136)
aPTT T2, s (n  288) 72 [58–93] (20–400)
alues are n (%) or median [interquartile range] (minimum–maximum).
aPTT  activated partial thromboplastin time; CABG  coronary artery bypass graft surgery; CT
clotting time; PCI  percutaneous coronary intervention; T1  time point 1; T2  time point 2.
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February 16, 2010:617–25 Bedside Enoxaparin Monitoringaseline analysis and distribution of anti-Xa levels. The
istribution of anti-Xa levels is represented in Figure 3, left
anel. The anticoagulation protocol led to optimal antico-
gulation in 95% of patients just before catheterization/PCI
T2). Only 14 patients (5.2%) had insufficient anticoagula-
ion (median anti-Xa  0.32 IU/ml; IQR: 0.17 to 0.47
U/ml), with 1 patient in the SQ plus IV group, 7 in the
V-only group, and 6 in the SQ-only group. Over-
nticoagulation, defined as an anti-Xa level 1.8 IU/ml,
ccurred only in 3 patients (1%) who all had an anti-Xa level
f 1.9 IU/ml. These 3 patients already had baseline anti-Xa
ctivity 0.5 IU/ml. The median anti-Xa levels of patients
ith an unknown anticoagulation status before catheteriza-
ion (n  14, transfer patients with limited chart informa-
ion) and who received a single IV bolus of enoxaparin (0.5
g/kg) were 0.65 IU/ml (IQR: 0.44 to 0.86 IU/ml) at T1
nd 1.14 IU/ml (IQR: 0.78 to 1.50 IU/ml) at T2, suggest-
ng that most of them probably received some anticoagula-
Figure 3 Biological Data
(Left) Hemonox clotting time distribution at time 1 (T1) and time 2 (T2). Horizonta
out-of-range low values (n  4) were not represented on the graph. (Right) Anti-Xa
percentiles (interquartile range). The bottom red line represents 0.5 IU/ml, and thion therapy before admission and T1 blood sampling. (aseline analysis and distribution of Hemonox CT. Dis-
ribution of Hemonox CT is represented in Figure 3,
ight panel. Median Hemonox CT was 74 s (IQR: 70 to
1 s) at baseline (T1) and 143 s (IQR: 114 to 206 s) at
2. Forty measurements (7.7%) were categorized as
ut-of-range by the Hemonox test; of those, 36 measure-
ents yielded “out of range high” results and 4 yielded
out of range low” results, which may indicate results
utside the upper and lower limits of the assay range.
hese values were kept in the analysis and were used as
ategorical variables for the calculation of ROC curves.
mong the 36 out-of-range high values, 34 (94.4%)
orresponded to patients with anticoagulation level 0.5
U/ml, and all the out-of-range low values corresponded
o patients with anti-Xa level 0.5 UI/ml.
elative response to IV enoxaparin. Anti-Xa level and
emonox CT were increased by 0.75 IU/ml (mean value
etween T1  0.14 IU/ml and T2  0.89 IU/ml) and 106 s
ars represent median and interquartile range. Out-of-range high (n  36) and
ty level at T1 and T2. Horizontal red bars represent median and 75th and 25th
red line represents 1.8 IU/ml.l red b
activi
e topmean value between T1 73 s and T2 179 s), respectively,
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Bedside Enoxaparin Monitoring February 16, 2010:617–25hen a 0.5 mg/kg IV bolus of enoxaparin was given. In
atients who received SQ enoxaparin and needed an additional
.25 mg/kg IV bolus of enoxaparin, anti-Xa level and He-
onox CT increased by 0.64 UI/ml (mean value between T1
0.32 IU/ml and T2  0.96 IU/ml) and 178 s (mean value
etween T1  86 s and T2  254 s), respectively.
valuation of the biological test. The correlation between
nti-Xa levels and Hemonox CT was stronger than the
orrelation between anti-Xa levels and aPTT, whether
nalyzed on the global T1 and T2 values (r  0.81, 95%
onfidence interval [CI]: 0.77 to 0.84, p  0.0001 vs. r 
.62, 95% CI: 0.56 to 0.68, p 0.0001) or separately on T1
r  0.45, 95% CI: 0.33 to 0.55, p  0.0001 vs. r  0.17,
5% CI: 0.036 to 0.31, p  0.01) and T2 values (r  0.39,
5% CI: 0.27 to 0.49, p  0.0001 vs. r  0.0085, 95% CI:
Figure 4 ROC Curves
Receiver-operating characteristic (ROC) curves for Hemonox clotting time in red
and activated partial thromboplastin time (aPTT) in blue for detection of patients
with anti-Xa level 0.5 IU/ml using the Chromogenic assay as reference.
ensitivity, Specificity, Likelihood Ratio, PPV, and NPVTable 3 Sensitivity, Specificity, Likelihood Ratio, PPV, and NPV
Hemonox CT, s Sensitivity Specificity
120 94.9 (91.1–97.4) 73.3 (67.6–78.5)
110 94.0 (89.9–96.8) 78.9 (73.5–83.6)
105 93.1 (88.8–96.1) 83.3 (78.3–87.6)
100 92.6 (88.2–95.7) 88.2 (83.7–91.8)
95 89.8 (85.0–93.5) 91.1 (87.1–94.2)
90 86.1 (80.8–90.4) 94.4 (91.0–96.9)
85 83.8 (78.2–88.4) 97.8 (95.2–99.2)
80 74.5 (68.2–80.2) 98.5 (96.2–99.6)
alues are % (95% confidence interval) unless otherwise noted. Sensitivity, specificity, likelihood ra
f Hemonox clotting time (CT) to detect patients with an anti-Xa activity 0.5 IU/ml. PPV indicates the pr
PV indicates the probability of having a negative test (Hemonox CT 120 s) when the anti-Xa activity is0.11 to 0.13, p  0.89). The ROC curves were calculated
or Hemonox CT and aPTT using the chromogenic mea-
urements of anti-Xa levels as the reference method to
iscriminate anti-Xa levels 0.5 IU/ml from those 0.5
U/ml (Fig. 4). When comparing all Hemonox CT values
ith corresponding anti-Xa levels, the area under the curve
as higher for Hemonox CT (0.95 0.01, 95% CI: 0.93 to
.97, p  0.0001; 486 values) than the bedside measure-
ents of aPTT (0.89  0.01, 95% CI: 0.86 to 0.92, p 
.0001; 480 values); results were confirmed by the Delong
Delong nonparametric test, with a difference of 0.06
95% CI: 0.03 to 0.09, p  0.0001).
Figure 5 Distribution of Hemonox CT
The blue line indicates a threshold of 120 s, identifying patients with anti-Xa activ-
ity 0.5 IU/ml with a sensitivity of 94.9% and a specificity of 73.9% when the
Hemonox clotting time is 120 s (positive test to identify patient with inadequate
level of anticoagulation). The horizontal red bars indicate median and interquartile
range.
Likelihood Ratio PPV NPV
3.5 73.9 (68.7–79.0) 94.8 (91.8–97.8)
4.4 78.0 (72.9–83.0) 94.3 (91.3–97.3)
5.6 81.6 (76.8–86.4) 93.8 (90.8–96.8)
7.8 86.2 (81.8–90.6) 93.8 (90.8–96.7)
10.1 89.0 (84.8–93.1) 91.9 (88.6–95.1)
15.5 92.5 (88.9–96.2) 89.5 (86.0–93.1)
37.7 96.8 (94.2–99.3) 88.4 (84.8–92.0)
50.3 97.6 (95.2–99.9) 83.0 (78.9–87.1)
itive predictive value (PPV), and negative predictive value (NPV) were calculated for each thresholdtio, pos
obability of having a positive test (Hemonox CT 120 s) when the anti-Xa activity is 0.5 IU/ml.
0.5 IU/ml.
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February 16, 2010:617–25 Bedside Enoxaparin Monitoringetection of patients with insufficient anticoagulation
herapy. The main purpose of a bedside test is the ability to
apidly measure the level of anticoagulation and identify
atients who are insufficiently anticoagulated with enoxaparin
t the time of PCI. We looked for the Hemonox CT threshold
alue having the best performance, especially in terms of
ensitivity to identify patients with an anti-Xa activity 0.5
I/ml. Different threshold values were evaluated and are
resented in Table 3. A threshold value of 120 s was associated
ith a 94.9% sensitivity (95% CI: 91.1% to 97.4%) and a
3.3% specificity (95% CI: 67.6% to 78.5%), with a likelihood
atio of 3.5 and an overall 83% (95% CI: 80% to 86%) accuracy
o detect patients with inadequate anti-Xa level (0.5 IU/ml)
Fig. 5). With this threshold, the positive and negative predic-
ive values of Hemonox CT as a diagnostic test were 73.9%
95% CI: 68.7% to 79.0%) and 94.78% (95% CI: 91.8% to
7.8%), respectively. A lower threshold value of 100 s im-
roved specificity to 88.2% (95% CI: 83.7% to 91.8%), with a
odest reduction of sensitivity of 92.6% (95% CI: 88.2% to
5.7%) and a likelihood ratio of 7.8 to detect patients with
nadequate anti-Xa level (0.5 UI/ml). With this threshold,
he positive and negative predictive values were 86.2% and
3.8%, respectively.
pecial populations. Obese patients (body mass index 30
g/m2; n  49 [16.5%]), exhibited higher levels of anti-Xa as
ompared with their nonobese counterparts (n 247 [83.5%],
.98 IU/ml [IQR: 0.84 to 1.15 IU/ml] vs. 0.86 IU/ml [IQR:
.72 to 1.00 IU/ml], p  0.0017). Similarly, Hemonox CT
as higher in obese patients than in nonobese patients (172 s
IQR: 120 to 364 s] vs. 139 s [IQR: 113 to 194 s], respectively;
 0.019). Patients with renal impairment (creatinine clear-
nce 60 ml/min; n  46 [15.5%]) had lower anti-Xa level
han patients with creatinine clearance 60 ml/min (n  250
84.5%], 0.82 IU/ml [IQR: 0.67 to 0.95 IU/ml] vs. 0.9 IU/ml
IQR: 0.77 to 1.08 IU/ml], respectively; p  0.006), and no
ifference in Hemonox CT values (144 s [IQR: 114 to 191 s]
s. 139 s [IQR: 113 to 210 s], respectively; p 0.9). In patients
ith severe renal impairment (creatinine clearance 30 ml/
in), anti-Xa level was 0.66 IU/ml (IQR: 0.57 to 1.06 IU/ml)
ersus 0.87 IU/ml (IQR: 0.75 to 1.03 IU/ml) in patients with
reatinine clearance 30 ml/min (p  0.12). Similarly, He-
onox CT was 148 s (IQR: 112 to 292 s) versus 154 s (IQR:
18 to 271 s, p  0.8), respectively.
In elderly patients (75 years of age; n  74 [25%]),
nti-Xa level and Hemonox CT values were similar to those
bserved in younger patients (n  222 [85%]; 0.84 IU/ml
IQR: 0.72 to 1.06 IU/ml] vs. 0.88 IU/ml [IQR: 0.74 to
.02 IU/ml], p  0.86; and 133 s [IQR: 108 to 191 s] vs.
43 s [IQR: 116 to 211 s], p  0.32, for anti-Xa and
emonox CT, respectively).
linical outcomes and safety. Among the 287 patients who
ompleted the follow-up, 3 died (1.0%) and 13 (4.5%) expe-
ienced an MACCE. Anti-Xa level was 0.76 IU/ml (IQR:
.55 to 1.07 IU/ml) versus 0.87 IU/ml (IQR: 0.74 to 1.03
U/ml, p  0.3) and Hemonox CT was 157 s (IQR: 100 to
1 s) versus 139 s (IQR: 113 to 200 s, p 0.9) in patients with rn  13) versus without (n  274) MACCE at 30 days,
espectively.
Bleeding rate was low, with 2 major bleedings (0.66%);
oth patients had an anti-Xa level 1.2 IU/ml. Among the
patients who died, 1 had a borderline anti-Xa level of 0.46
U/ml (the respective Hemonox CT was 95 s), the second
ad an anti-XA level of 0.6 IU/ml (the respective Hemonox
T was 140 s), and the third had an unknown anti-Xa value
t T2 but Hemonox CT was 78 s.
iscussion
he main purpose of a LMWH enoxaparin bedside test
s the ability to rapidly and reliably monitor enoxaparin
nticoagulation therapy in patients managed with SQ
oses who transit to PCI or in patients receiving IV bolus
uring cardiac interventional procedure, and ensure that
atients receive adequate anticoagulation therapy before
he start of the procedure. Thus, the sensitivity of the
edside test is critical. We demonstrate in this report that
noxaparin-treated patients with inadequate anti-Xa ac-
ivity (0.5 IU/ml) can be accurately and easily identified
y the Hemonox bedside test, with a high sensitivity
94.9%) when using a 120 s threshold. This threshold
llows clinicians to rule out the need for additional
nticoagulation therapy when levels are beyond 120 s,
ith a good negative predictive value (94.8%). The ROC
urves and the good correlation between Hemonox CT
nd the anti-Xa level measured with the chromogenic
ethod confirm the accuracy of this bedside test in the
hole range of values obtained in our population. In
ontrast, and not surprisingly, bedside aPTT measure-
ent was less sensitive.
Despite increasing evidence on the equivalent efficacy
nd superior safety of enoxaparin as compared with UFH,
noxaparin is still not widely used in patients undergoing
CI (3). The inability to rapidly monitor the anticoagu-
ant effect of enoxaparin in a similar fashion as the
ctivated clotting time with UFH has limited the use of
noxaparin in interventional cardiac procedures. This
tudy demonstrates that Hemonox is a suitable bedside
est and is easy to use in the catheterization laboratory for
onitoring the anticoagulation level of enoxaparin in
atients undergoing PCI.
Several studies have shown that an SQ upstream treat-
ent by enoxaparin at the dose of 1 mg/kg twice daily (0.65
g/kg twice daily for patients with impaired renal function)
llows adequate anticoagulation for PCI within 8 h of the
ast injection, whereas an additional IV bolus of 0.25 to 0.30
g/kg is needed (13,15,16) if the last SQ was injected more
han 8 h and less than 12 h before the procedure. Our work
onfirms that this enoxaparin dose regimen is associated
ith an anti-Xa activity in the therapeutic range (0.5 to 1.8
U/ml) in the large majority of patients (95%) with low rates
f under- or over-anticoagulated patients (4% and 1%,
espectively). However, patients undergoing PCI with an
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Bedside Enoxaparin Monitoring February 16, 2010:617–25nti-Xa activity 0.5 IU/ml may be at high risk of ischemic
omplications. Only a few studies have been conducted with
ufficient power to assess correlations between target
nti-Xa levels and outcomes of ischemic complications
17,18). A recent study involving unstable angina/non-
TEMI patients reported a 3-fold increase in 30-day
ortality associated with suboptimal anticoagulation
anti-Xa levels 0.5 IU/ml) (7). Such findings suggest the
eed for monitoring anti-Xa activity with a rapid point-of-
are test to identify the patients who require dose adjust-
ent.
Our Hemonox results are in agreement with those
eported from previous studies conducted on a small sample
ize (5,6). Additionally, the study was conducted in a
opulation treated exclusively with enoxaparin and included
pecial patient groups such as patients with renal failure, the
lderly, and obese patients. The absence of over-
nticoagulation therapy for these specific patient popula-
ions shows the effectiveness of the protocol used and
onfirms previous results (19). Nevertheless, results from
his study suggest the utility of the point-of-care test in
onitoring enoxaparin in special patient.
Because the main objective of the monitoring test is its
evel of sensitivity for defining patients who are under-
nticoagulated, the threshold of 120 s may be recom-
ended, especially in patients at high risk of thrombosis. In
ther words, if Hemonox CT is 120 s in the catheteriza-
ion laboratory, an additional IV enoxaparin bolus of 0.5
g/kg could be given to the patient before PCI to ensure
chieving an effective anti-Xa level within the therapeutic
ange (0.5 to 1.8 IU/ml). Our results indicate that for
atients without any prior anticoagulation, an IV enoxapa-
in bolus of 0.5 mg/kg yields an average anti-Xa activity
evel of 0.73 IU/ml. Thus, patients with a Hemonox CT
alue 120 s but with some residual anti-Xa activity (0.5
U/ml) would not be over-anticoagulated with an additional
V bolus (15). Actually, we observed this scenario in a few
atients of our study whose anticoagulation status was
nknown at the time of catheterization; they received an IV
olus of 0.5 mg/kg and remained within the recommended
herapeutic range of anti-Xa level.
A more graded approach to Hemonox CT could be used;
ower cutoff values (100 s) would increase specificity, which
ay be useful in stable patients and/or patients at high risk
f bleeding; additional IV enoxaparin doses 0.5 mg/kg
ould also be used in patients with Hemonox CT 80 to
20 s.
All these strategies would have to be tested prospectively
n further studies as well as the value of bedside enoxaparin
onitoring in situations such as STEMI patients treated
ith fibrinolytic drugs or anticoagulation therapy during
emodialysis.
In daily practice, the Hemonox test may be used in the
atheterization laboratory to assess the appropriate level of
nticoagulation therapy in patients undergoing PCI and to
void the use of UFH in addition to enoxaparin, as is still
1one by some interventionists and has been shown to be
ssociated with worse outcome in the SYNERGY (Superior
ield of the New Strategy of Enoxaparin, Revascularization
nd Glycoprotein IIb/IIIa Inhibitors) trial (20).
tudy limitations. One important limitation of our study
s that it was not powered to assess the impact of the
emonox CT on clinical outcomes. Another limitation is
he limited information obtained on high levels of antico-
gulation, as very few patients in our population reached
nti-Xa values 1.8 IU/ml. Finally, the cost effectiveness of
monitoring-guided strategy of enoxaparin anticoagulation
herapy remains to be established.
onclusions
ccording to the results of this study, Hemonox CT
ppears to be a fast and reliable bedside test that can be used
o monitor enoxaparin anticoagulation therapy immediately
efore catheterization and PCI.
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